Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v2.4.0.8
Commitments and Contingencies (Details Textual) (USD $)
3 Months Ended 9 Months Ended 0 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 0 Months Ended 1 Months Ended 9 Months Ended 12 Months Ended 0 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Jun. 20, 2014
Dec. 31, 2013
Jan. 27, 2014
Manufacturing Agreement [Member]
Sep. 30, 2014
Manufacturing Agreement [Member]
Sep. 30, 2014
Einstein [Member]
Sep. 30, 2014
Abbview Biotherapeutics Corp [Member]
Product Development and Patent License Agreement [Member]
Sep. 30, 2014
Abbview Biotherapeutics Corp [Member]
After First Net Sales [Member]
Sep. 30, 2014
Abbview Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
Sep. 30, 2014
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
Product Development and Patent License Agreement [Member]
Sep. 30, 2014
Abbott Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
Sep. 30, 2014
Oak Ridge National Laboratory [Member]
2013 [Member]
Sep. 30, 2014
Oak Ridge National Laboratory [Member]
2014 [Member]
May 16, 2013
Aptiv Solutions [Member]
Oct. 22, 2012
Aptiv Solutions [Member]
Aug. 06, 2012
Aptiv Solutions [Member]
Dec. 31, 2007
Aptiv Solutions [Member]
Sep. 30, 2014
Aptiv Solutions [Member]
Dec. 31, 2012
Aptiv Solutions [Member]
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Sep. 30, 2014
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Sep. 30, 2013
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Sep. 30, 2014
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
Dec. 31, 2013
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
Jul. 19, 2012
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
Maximum [Member]
license and sponsored research agreement [Member]
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
Minimum [Member]
license and sponsored research agreement [Member]
Aug. 28, 2012
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
patients
Sep. 30, 2014
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
Jul. 31, 2013
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
Sep. 26, 2012
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
Sep. 30, 2014
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
Sep. 30, 2014
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
Dec. 31, 2013
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
Nov. 21, 2012
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
Commitments and Contingencies (Textual)                                                                            
Net sales in milestones payment                         $ 10,000,000                                                  
License fee payment                   3,000,000                                                        
Milestones payments                   7,750,000 1,500,000 750,000   750,000                 1,000,000                              
Description of royalty payment                   Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.                           Royalty payments of 2% of net sales will be due to FHCRC.                            
Royalty of net sales percentage                   12.00%                         2.00%                              
First commercial sale period                   12 years 6 months                                                        
Purchase of radioactive material used for research and development                             300,000 400,000                                            
Project estimated cost for clinical trials of drug Ac-225-HuM195             3,300,000 2,300,000                 2,200,000 2,200,000 2,200,000   1,200,000                                  
Down payment of project estimated cost percentage                                         12.50%                                  
Down payment for project                                     1,900,000 239,000   239,000                                
Clinical trial cost for approval of food and drug administration                                                         23,500,000 13,200,000                
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )                                             150,000                              
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )                                             250,000                              
Number of Patients                                                             24              
Amount paid to each patient after Completing clinical trial                                                   16,000   31,366     500,000   34,383 38,501        31,771
Start-up fee for clinical trial                                                     19,749       33,946     22,847       16,000
Start-up due cost paid date                                                             Dec. 31, 2013              
Non - refundable institutional fee             562,790                                               14,500              
Annual pharmacy fee                                                                   2,025        
Amendment processing fee                                                                   500        
Accrued expenses                                                                         16,000  
Accrued fees paid                                                                       16,000    
Research recorded fees 3,773,438 778,232 8,236,343 2,373,200                                       100,000 75,000             100,000       16,000    
Total project estimated to cost         800,000       183,391                                                          
Research and development costs 300,000               92,000                                                          
Security deposit $ 34,733   $ 34,733